Lannett receives FDA approval for generic Ionamin

PHILADELPHIA — The Food and Drug Administration has approved a generic version of a short-term adjunct treatment for obesity.

Lannett said that the FDA approved its abbreviated new drug application for phentermine resin extended-release capsules in the 15-mg and 30-mg strengths. The drug, which is equivalent to UCB's Ionamin, will be sold in bariatric clinics.

Lannett’s wholly owned pain management subsidiary, Cody Labs, will produce the active pharmaceutical ingredient for this product. The drug is indicated in the management of exogenous obesity, a form of obesity caused by excessive food intake.